{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-239687","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.380656+00:00","generated_at":"2026-05-30T12:51:15.506089+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors","bullets":["Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.","Errors: weighted average ordinary shares outstanding incorrectly used ending shares instead of weighted average.","Restatement affects only IFRS-based financials in 2022 Annual Report; 2023 US GAAP financials not impacted.","Company intends to file amendment to 2022 Annual Report as soon as practicable."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-239687","json":"https://secwatch.observer/filing/0001193125-24-239687.json","markdown":"https://secwatch.observer/filing/0001193125-24-239687.md","text":"https://secwatch.observer/filing/0001193125-24-239687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524239687/0001193125-24-239687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524239687/d894508d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:51:15.506089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}